Care Bare Rx vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Care Bare Rx
Best for LGBTQ+-inclusive compounded GLP-1 telehealthStarting at $199/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | Care Bare Rx | Wisp |
|---|---|---|
| Overall Score | ✓7.4/10 | 7.0/10 |
| Starting Price | ✓$199/mo | $225/mo |
| Editorial Rating | ✓3.7 ★ /5 | 3.5 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Care Bare Rx
Pros
- ✓Explicit LGBTQ+-inclusive, 'self-care with pride' positioning — one of the few GLP-1 telehealth brands with this framing
- ✓All 50 states + Puerto Rico coverage
- ✓Offers both compounded options ($199/mo) and brand-name Ozempic ($705/mo) — unusual flexibility in the compounded-first telehealth segment
- ✓Same named medical team as Breeze Meds and Synergy Rx: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
- ✓Four named 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx)
- ✓No FDA warnings or litigation on record
Cons
- ✗Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Breeze Meds and Synergy Rx — the three brands are white-labeled storefronts on top of one underlying operation, not three independent providers
- ✗Compounded medications are not FDA-approved
- ✗Despite the LGBTQ+ positioning, no formal gender-affirming care pathway or HRT integration is mentioned — the inclusive framing is editorial rather than a clinical specialty
- ✗Limited accreditation transparency beyond LegitScript claim — no PCAB/ACHC seal on site
- ✗Pharmacy partners are named but per-batch third-party testing and accreditation details are not independently disclosed
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Care Bare Rx edges out Wisp with a higher overall score of 7.4/10 and is particularly strong for LGBTQ+-inclusive compounded GLP-1 telehealth. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.